Background: In two phase 3 trials, elobixibat, a locally acting ileal bile acid trans-
| INTRODUC TI ON
Constipation is self-reported by 27 .2% of North American adults 1 and 28.4% of Japanese adults, 2 although the prevalence differs with the definition used. The symptoms of chronic constipation are infrequent bowel movements, straining, a sensation of incomplete evacuation, and the presence of hard stools. 3 These negatively affect quality of life (QOL) and impose socioeconomic burdens. 4 In the absence of rectal evacuation disorders, most patients with constipation have normal colonic transit, but a few have slow colonic transit 5 associated with reduced colonic propagated contractions. 6 Lower levels of 48-hour fecal excretion of total and secretory bile acids (BAs), such as deoxycholic and chenodeoxycholic acids, are associated with constipation. 7 Total fecal BA excretion and fasting serum 7-α-hydroxy-cholesten-one (a surrogate marker of BA synthesis)
have also been associated with slow colonic transit. 8 Elobixibat (PubChem CID: 9939892) is a minimally absorbed inhibitor of the ileal BA transporter (IBAT, also called apical sodiumdependent BA transporter). Approved in Japan in January 2018 for the treatment of chronic constipation, this IBAT inhibitor interrupts the enterohepatic circulation of BAs and upregulates hepatic BA synthesis. 9 Increased concentrations of BAs in the colon then enhance colonic transit by stimulating fluid and electrolyte secretion 10 and by inducing high-amplitude propagated contractions (HAPCs), as demonstrated experimentally by the effects of intraluminal chenodeoxycholate. 11 In phase 2 clinical trials in North America, elobixibat significantly accelerated colonic transit and improved bowel function 12, 13 ; in dogs, it successfully induced HAPCs. 14 Complementing the existing research, our research groups have recently published the results of phase 1, 2, and 3 trials in Japan. [15] [16] [17] Among these, there have been two phase 3 trials sharing similar methodologies. The first was a randomized, double-blind, placebocontrolled, 2-week trial in Japanese patients with chronic constipation, which showed that 10 mg of elobixibat once daily was safe and effective. The second was an open-label, single-arm, 52-week trial, which showed that 5-15 mg of elobixibat once daily was well tolerated, safe and improved QOL from baseline, and the most common adverse drug reactions (ADRs) of elobixibat were mild diarrhea or mild abdominal pain.
Previously, it was reported that experiencing <2 bowel movements per week or having a mean stool consistency of <3 on the Bristol Stool Form Scale (BSFS) score for 5 days could be used as independent predictors of slow transit constipation in Western cohorts. 18, 19 In addition, recent reports in Eastern cohorts demonstrated that ≤2 bowel movements and ≤3 mean BSFS score for 5 days could be a valid predictive marker for slow colonic transit. 20 To date, however, there has been no research to indicate whether elobixibat is effective in cases of more severe constipation that may be associated with slow transit constipation.
In this study, we aimed to assess the efficacy, safety and impact on QOL of elobixibat in specific patient subgroups, particularly focusing on baseline characteristics of severe constipation (defined as ≤2 spontaneous bowel movements [SBM] and ≤3 mean BSFS score measured in the second week of the 2-week run-in period), sex, and presence of features consistent with constipation-predominant irritable bowel syndrome (IBS-C).
| MATERIAL S AND ME THODS

| Study design
This post hoc analysis was based on previously reported data from the 2-week, randomized, controlled trial (JapicCTI-153062, or the "2-week trial") and the 52-week, open-label trial (JapicCTI-153061, or the "52-week trial"), the designs of which have been described in detail previously. 17 In both trials, there was a 2-week run-in period before the eligible patients took the study drug for the study duration as an oral tablet before breakfast, once per day. Patients were monitored in an outpatient setting at each study site. In the 2-week trial, 10 mg elobixibat or a placebo was taken once per day for 2 weeks (single cycle). In the 52-week trial, participants received elobixibat oral tablets for 52 weeks at a dose of 10 mg/d for the first week; thereafter, patients could titrate the dose to 5 or 15 mg/d, or maintain the 10 mg/d dose, based on the effectiveness of the drug and the development of ADRs.
| Participants
Males and females (non-pregnant), aged ≥20 years, were included in the study if they satisfied the Rome III criteria for the diagnosis of functional constipation. 21 Patients with IBS-C were included in both trials. Patients were excluded if their chronic constipation was caused by organic disorders of the intestine (mechanical obstruction or neurological, endocrine, or metabolic disorders), medications, or intestinal or rectal surgery (except for simple appendectomy).
Finally, participants in the 2-week trial were excluded from the 52-week, open-label trial.
Key Points
• Elobixibat was effective and well tolerated for patients with chronic constipation in two Japanese phase 3 trials.
We conducted post hoc analyses in patients with severe constipation in the trials.
• Significant improvement in spontaneous bowel movements in the 10 mg elobixibat group was observed during week 1 (primary endpoint) compared with the placebo group.
• Elobixibat was well tolerated and improved quality of life, irrespective of patient background or experience of side effects of abdominal pain and diarrhea.
| Post hoc analysis of efficacy
All efficacy analyses, including post hoc analyses, were based on a modified intention-to-treat population (ie, defined as patients who received at least one dose of the study drug). 17 Subgroup analysis of efficacy was performed among subgroups by IBS-C diagnosis (with and without), sex, age (<65 and ≥65 years), or more severe constipation. This final criterion was classified into three groups based on the occurrence of SBMs and mean BSFS score during the second week of the 2-week run-in period: severe constipation with SBM ≤2 and BSFS score ≤3; very severe constipation with SBM ≤1 and BSFS score ≤3; or absolute constipation if SBM = 0. We used modified SBM and BSFS score criteria from the previous report 20 and assessed symptoms over a more rigorous period of 7 days rather than 5 days.
The efficacy endpoints were the same as previously reported. 17 The primary endpoint of the 2-week trial was the change from base- we included time to first CSBM. 17 The subgroup post hoc analyses of efficacy were not prespecified except for prespecified subgroup analysis of the primary endpoint among subgroups by IBS-C diagnosis, sex, and age.
In the 52-week trial, data were recorded for each treatment week and at baseline. No treatment was received during the 2-week run-in period in either study.
| Post hoc analysis of safety and QOL
The safety analyses relied on the data for all patients who received at least one dose of the study drug. In the 52-week trial, the primary outcome was safety based on the presence of ADRs, with mild abdominal pain and diarrhea being most common. For the post hoc analysis of safety, we analyzed subgroups based on age, sex, and IBS-C diagnosis to identify differences in the incidence (%), the median number of days to first onset, and the median number of days to resolution of abdominal pain and diarrhea.
The efficacy endpoint in the 52-week trial also included an as- 
| Statistical analysis
For the primary endpoint (changes in SBM frequency) and changes in CSBM frequency in the first week of the 2-week trial, differences in the least squares means with 95% confidence intervals (CIs) between elobixibat and placebo were estimated using analysis of covariance (ANCOVA) model; models with different variances were used in the elobixibat and placebo groups. Odds ratios (OR) with 95% CIs for the proportions of SBM or CSBM responder rates in the elobixibat group vs placebo group were calculated using Firth's penalized likelihood logistic regression model. Hazard ratios (HR) with 95% CIs for the time to first SBM or CSBM in the elobixibat group vs the placebo group were estimated using Cox regression model with the same effects as logistic regression. Interaction terms of treatment by subgroup were included in each model, and tests of interaction among subgroups were also performed. The median times to first SBM were assessed by the Kaplan-Meier method.
In the 52-week trial, the numbers and proportions of patients who had abdominal pain or diarrhea were summarized, and we assessed the differences with 95% CIs between subgroups. The 95%
CIs for risk difference in ADRs were calculated using Newcombe's method. Statistical comparison of the QOL subscale scores from baseline was performed using t test, and the mean differences with 95% CIs were calculated for the overall JPAC-QOL scores of each subgroup during the 52-week treatment period.
All P-values were based on two-sided tests, and the significance level was set at 0.05. All data were analyzed using SAS 9.4 (SAS Institute Inc, Cary, NC, USA) and were provided by EA Pharma Co., Ltd. Table 1 shows the SBMs or CSBMs baseline characteristics of the included populations or subgroups that satisfied the criteria for severe constipation in the second week of the 2-week run-in period before the 2-week and 52-week trials. The data of the included participants were derived from those previously reported. 17 As shown, both
| RE SULTS
| Baseline bowel movements
SBMs and CSBMs between placebo and elobixibat in each subgroup were well balanced except for CSBMs in patients with not severe constipation.
| Post hoc analysis of efficacy in patients with severe constipation
In the 2-week trial, significant improvements in the primary endpoint (change in SBMs from baseline at week 1) were observed in differences between the 10 mg elobixibat group and the placebo group in the subgroups except for absolute constipation ( Figure 1A ). The efficacy results for the severe constipation subgroup were similar to the efficacy in the total patient cohort. The differences between elobixibat and placebo groups were reduced in patients with more severe constipation. Thus, differences between elobixibat and placebo (95% CI; lower limit, upper limit) for severe constipation/very severe constipation/absolute constipation were 4.9 (3.3, 6.5), 3.8 The median time to first SBM after elobixibat was similar between the total cohort and the severe constipation subgroup (5.1 and 5.6 hours, respectively), and was also similar for the total cohort and severe constipation subgroup treated with placebo (25.5 and 25.0 hours, respectively). In the very severe constipation subgroup, the median time to first SBM after elobixibat was 5.0 hours, which was significantly faster than the placebo treatment group (46.0 hours) and comparable to the entire constipation cohort and the severe constipation group.
Numbers needed to treat (NNTs) were calculated for the SBM and CSBM responder rates at week 1. NNTs for the SBM/CSBM response in the total constipation cohort were 2.9/2.9, severe constipation subgroup 3.6/3.1, and very severe constipation subgroup 2.8/3.6.
In the 52-week trial, the mean weekly change in SBMs and
CSBMs from baseline increased consistently in the severe, very severe, and absolute constipation subgroups, which were comparable to the changes observed in the whole constipation cohort (Figure 3 ).
In patients with IBS-C or without IBS-C, the mean weekly change in SBMs and CSBMs from baseline increased equally, irrespective of IBS-C status. A summary of treatment titration between the 5, 10 and 15 mg doses over the 52 weeks is shown in Table 2 . As the severity of the baseline constipation increased, more patients titrated TA In the 52-wk trial, participants received elobixibat oral tablets for 52 wk at a dose of 10 mg/d for the first week; thereafter, patients could titrate the dose to 5 or 15 mg/d, or maintain the 10 mg/d dose, based on the effectiveness of the drug and the development of adverse drug reactions.
to the elobixibat 15 mg dose, the treatment duration at the 15 mg dose increased, and the proportion of patients still taking that dose in the last 4 weeks of the 52-week trial increased. Table 3 shows the safety summary, focusing on abdominal pain and diarrhea, as reported in the 52-week trial. There were no significant differences in the frequency of either abdominal pain or diarrhea in relation to IBS-C or sex. Among patients aged ≥65 years, only one experienced abdominal pain and only three experienced diarrhea.
| Post hoc analysis of safety and QOL in patients with severe constipation
Excluding males and patients aged ≥65 years, due to small sample sizes, the median times to the first onset of abdominal pain and diarrhea were 1-3 and 17-28 days, respectively; the corresponding median times to resolution were 15-17 and 5-8 days, respectively.
Based on the sub-score analysis of the JPAC-QOL (Table 4A) , elobixibat significantly improved physical discomfort, psychosocial discomfort, worries and concerns, satisfaction, and overall JPAC-QOL scores compared with baseline. In the subgroup analysis of the overall JPAC-QOL scores (Table 4B) , no clinically significant differences were observed in relation to sex, IBS-C status, or experience of abdominal pain or diarrhea as ADRs.
| D ISCUSS I ON
In this post hoc analysis, we assessed the efficacy of elobixibat in patients with severe chronic constipation based on a combination of SBM and BSFS criteria, which may be a predictive marker of slow transit constipation. Elobixibat at a 10 mg dose produced significant improvements in SBM-and CSBM-based endpoints in the 2-week trial, although its efficacy decreased with increased baseline severity of constipation, as determined from the baseline frequency of SBMs.
Long-term improvements tended to be observed in patients with fewer SBMs at baseline, but these remained comparable to those Difference, % (95% CI) −1 (−9, 8) --Data show the number of patients % (n) for incidence, the difference % of the number of patients (95% CI: lower limit, upper limit) between groups, or the median day interquartile range (IQR) for the first onset or resolution. CI, confidence interval; IBS-C, constipation-predominant irritable bowel syndrome; IQR, interquartile range. The patient experienced at least one event over the 52 wk.
TA B L E 4
* P < 0.0001 compared with baseline (t test).
in the total study population because the elobixibat dose could be increased to 15 mg if the effect was not sufficient at the lower dose.
We analyzed the data of 157 patients to evaluate the incidence of ADRs, specifically abdominal pain and diarrhea, from 2 weeks before to 2 weeks after the first dose increase to 15 mg; there was no increase in the incidence of ADRs after increasing the dose. In addition, the incidences of adverse events in the 5, 10, and 15 mg groups were not dose dependent in the Japanese phase IIb study, 16 and from this post hoc analysis, elobixibat was well tolerated and improved the JPAC-QOL score in each subgroup. In fact, most ADR reports were of mild severity, and the majority of patients recovered without titrating dose down and the JPAC-QOL score still improved, implying that tolerability and safety were good.
Patients with and without IBS-C showed similar improvements in the primary endpoint at week 1 in the 2-week trial; these two groups also showed consistently higher frequencies of SBMs and
CSBMs during the 52-week trial. Moreover, elobixibat was well tolerated in terms of abdominal pain and diarrhea, which were observed with similar incidence in those with IBS-C diagnosis compared to the rest of the cohort; similarly, there were no significant differences between the two groups in the JPAC-QOL scores in the 52-week trial. It has been speculated that the abdominal pain experienced by some while taking elobixibat might be different from that of IBS because elobixibat induces HAPCs, 14 which might be associated with mass movements and short-lived pain due to the temporary increase in colonic pressure. Other potential mechanisms for the abdominal pain may result from the increased colonic BAs, since BAs reduced rectal sensory thresholds in humans 11 and increased mucosal permeability in rabbits. 22 The mechanisms whereby elobixibat results in symptom relief in IBS should be a topic for future research.
An NNT analysis was provided to allow comparison with other drugs, but there are important considerations when interpreting this for chronic constipation. 23, 24 For example, it is ideal that relief from chronic constipation by medication be observed as soon after administration as possible. In our study, we appraised NNT for weekly SBM and CSBM responder rates at week 1 for the entire patient cohort were both 3, and the NNTs ranged from 3 to 4 in the severe to very severe constipation groups. These data suggest that elobixibat is effective for both normal and slow transit constipation because of the rapid onset of efficacy.
Given that the mean 5-day BSFS score of ≤3 provided 68.0% sensitivity, 69.7% specificity, and 69.4% accuracy, and that the stool frequency of ≤2 bowel movements in 5 days provided 64.0% sensitivity, 83.1% specificity, and 84.0% accuracy for predicting delayed colonic transit time, 20 it is possible that the patients in- 
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